Product Hopping, Product Withdrawal
12 PM EDT
Two recent cases, New York v. Actavis PLC and In re: Suboxone Antitrust Litigation address monopolization claims related to “product hopping” – the phenomenon where a branded pharmaceutical company tries to convert patients from a branded drug facing patent expiration to a newer version with different attributes that remain patented. This program will bring together leading litigators from both sides of these issues to discuss when product hopping raises antitrust issues and how courts should address them.
* Nicholas Widnell, Boies, Schiller & Flexner LLP
* Mark A. Ford, WimerHale
* Elinor Hoffman, New York State Office of the Attorney General
* Mark R. Lentz, Jones Day
* Steven Shadowen, Hilliard & Shadowen LLP
Attending In Person?
51 Louisiana Avenue, N.W.
Washington, DC 20001
*Please note that program materials are only available to registrants and are not to be further distributed.*
FREE: Antitrust Section Members, Government, Nonprofit Employees and Students
$25.00: Other Non-Members
Learn about Section Membership or call 800-285-2221 to join with source code: RAT14IP25. Instructions for accessing the live program will be provided in a confirmation email. For this and all upcoming events visit: http://AmBar.org/ATEvents.
The ABA is not seeking CLE credit for this program.
Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.